Please login to the form below
companion diagnostic
This page shows the latest companion diagnostic news and features for those working in and with pharma, biotech and healthcare.
Loxo, Bayer get quick FDA review for ‘precision’ cancer drug
To try to address that issue, Loxo formed a partnership earlier this year with Illumina to develop a companion diagnostic – called TruSight Tumour 170 – that will use sequencing to identify whether
Latest news
-
EMA starts firming up its stance on personalised medicines
New draft European guidelines on personalised medicines and companion diagnostics are expected to be released by December 2018. ... As diagnostic medical devices, companion diagnostics do not fall within the oversight of the EMA, but the regulator is set
-
Celgene, Agios get FDA OK for leukaemia drug Idhifa
A companion diagnostic from Abbott Labs that detects mutations in the IDH2 gene in blood or bone marrow samples has been approved alongside the new drug.
-
AZ takes Chi-Med’s kidney cancer drug into phase III
He noted that the company has developed a companion diagnostic that will be used to select patients for its phase III programme.
-
AZ gets first OK for PD-L1 inhibitor durvalumab
The FDA also approved Roche's Ventana PD-L1 assay as a companion diagnostic for assessing PD-L1 protein levels in biopsy tissue.
-
Novartis' Rydapt approval ends long AML therapy drought
The US agency cleared Novartis' Rydapt (midostaurin) for use alongside chemotherapy in newly-diagnosed AML patients who carry the FLT3 mutation, also giving the okay for a FLT3 companion diagnostic developed
More from news
Approximately 1 fully matching, plus 66 partially matching documents found.
Latest Intelligence
-
Harnessing complexity
This delicate balance between companion diagnostics' clinical utility and their potential confounding impact on patient treatment is a growing dilemma. ... Answering this question in full requires a scientific journey to better understand what a
-
Diagnostics are rising up the pharma value chain
Diagnostic drivers. It's not just this idea of changing public attitudes that is creating renewed interest in the diagnostics sector; the sector is also influenced by the wider forces affecting ... GlaxoSmithKline and Boehringer Ingelheim have had
-
Deal Watch table for June 2014
50. NanoString Technologies/ Celgene. Development. Development of a companion diagnostic assay.
-
Pharma deals during June 2014
a deal with NanoString Technologies for the development of a companion diagnostic assay to support the development of Revlimid for treatment of Diffuse Large B-Cell Lymphoma at a more modest
-
Interview: John Dineen, GE Healthcare
some of these markers can be converted into a companion diagnostic product after the completion of a late-stage clinical trial. ... We can then ensure our diagnostic is closely coupled with the therapeutic capability.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Featured jobs
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Business Unit Head, Medical Communications, London
-
Excellent package
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- MaxCyte gets green light for solid tumour cell therapy
- Brexit rebels win vote on European Medicines Agency alignment
- Positive mid-stage trial gives Allergy’s investors some welcome relief
- Random42 win Creativity International Award for Scientific Animation
- Merck & Co joins big pharma pricing pledge – but sceptics unconvinced
- Aurora partners with PIPHealth and taps into patient panels
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
PMHub
EY Life Sciences
Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
